Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;16(8):e013009.
doi: 10.1161/CIRCINTERVENTIONS.123.013009. Epub 2023 Jul 17.

Vascular Access in Percutaneous Coronary Intervention of Chronic Total Occlusions: A State-of-the-Art Review

Affiliations
Review

Vascular Access in Percutaneous Coronary Intervention of Chronic Total Occlusions: A State-of-the-Art Review

Thomas A Meijers et al. Circ Cardiovasc Interv. 2023 Aug.

Abstract

The outcomes of chronic total occlusion percutaneous coronary intervention have considerably improved during the last decade with continued emphasis on improving procedural safety. Vascular access site bleeding remains one of the most frequent complications. Several procedural strategies have been implemented to reduce the rate of vascular access site complications. This state-of-the-art review summarizes and describes the current evidence on optimal vascular access strategies for chronic total occlusion percutaneous coronary intervention.

Keywords: consensus; hemorrhage; percutaneous coronary intervention; vascular diseases.

PubMed Disclaimer

Conflict of interest statement

Disclosures Drs Aminian and Dens are consultants for Terumo Corporation. Dr Iglesias is a consultant for Biotronik, Cordis, Medtronic, and Terumo Corporation; has received unrestricted research grants to the institution from Abbott Vascular, AstraZeneca, Biotronik, Biosensors, Concept Medical, Philips Volcano, and Terumo Corporation; and has received honoraria/speaker fees for AstraZeneca, Biosensors, Biotronik, Bristol Myers Squibb/Pfizer, Cordis, Concept Medical, Medalliance, Medtronic, Novartis, Terumo Corporation, and Philips Volcano. Dr Brilakis has received consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Amgen, Asahi Intecc, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), Cardiovascular Systems, Inc, Elsevier, GE Healthcare, Interventional Medical Device Solutions (IMDS), Medicure, Medtronic, Siemens, Teleflex, and Terumo Corporation; has received research support from Boston Scientific and GE Healthcare; is the owner at Hippocrates LLC; and is a shareholder at MHI Ventures, Cleerly Health, and Stallion Medical. Dr Gasparini reports consulting/speaker honoraria from Abbott Vascular, Cordis, Terumo Corporation, Asahi Intecc, IMDS, Boston Scientific, and Medtronic. Dr Valgimigli reports personal fees from AstraZeneca, grants and personal fees from Terumo Corporation, personal fees from Alvimedica/Carbostent and Implantable Devices, personal fees from Abbott Vascular, personal fees from Daiichi Sankyo, personal fees from Bayer, personal fees from Abiomed, personal fees from CoreFLOW, personal fees from Idorsia Pharmaceuticals, Ltd, personal fees from Universität Basel, Deptartment Klinische Forschung, personal fees from Bristol Myers Squib SA, personal fees from Medscape, personal fees from Biotronik, and personal fees from Novartis, outside the submitted work. Dr van Royen received research grants from Philips, Abbott, Biotronik, and Medtronic and personal fees from Abbott, Microport, and Rainmed. Dr van Leeuwen received speaker/consulting services honoraria from Terumo Corporation, Daiichi Sankyo, and Abbott and research grants from AstraZeneca, Top Sector Life Sciences & Health, Terumo Corporation, Top Medical B.V., and Abbott. The other authors report no conflicts.

MeSH terms

LinkOut - more resources